Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
183
resultados
Última actualización
30/05/2025 [06:52:00]
Resultados 50 a 75 de 183
Resumen de: US2025161498A1
The invention provides microbubbles and PSMB labeled with targeting ligands that are useful in the detection and treatment of vascular thromboses (e.g., fibrin clots) and vascular plaques, or related diseases and conditions, as well as methods of preparation and use thereof.
Resumen de: US2025161496A1
Described herein are synthetic promoters and/or enhancers that are specific for cancer cells and methods of engineering synthetic cancer-specific promoters.
Resumen de: US2025161491A1
Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.
Resumen de: WO2025104091A1
The present invention relates to functionalized nano- or microparticles of suitable size and shape, comprising a nano- or microparticle and at least one virus-binding peptide and/or virus-binding small molecule immobilized onto the surface of the nano- or microparticle. These nano- or microparticle forms aggregates with targeted viral particles to initiate phagocytosis, thereby achieving viral clearance. The present invention further relates to uses of the functionalized nano- or microparticles in virus detection, therapy and diagnosis.
Resumen de: US2025161481A1
Disclosed are lipid nanoparticle (LNP) delivery systems that specifically target T cells. The LNP delivery system comprises antibodies conjugated to the surface of the LNP, e.g., via maleimide chemistry, that target at least two T cell surface proteins, e.g., CD3 and CD28. The LNP delivery system can have a single population of LNP conjugated to either a bispecific antiCD3/antiCD28 antibody, or two monospecific antiCD3 and antiCD28 antibodies, or two populations of LNP wherein each population comprises a monospecific antibody. The payload of the LNP delivery system can be, e.g., mRNA encoding chimeric antigen receptors (CAR), a linear DNA fragment or a plasmid encoding chimeric antigen receptors (CAR) or therapeutic proteins such as antibodies, components of a gene editing systems (e.g., CRISPR-Cas), small molecules, antibody-drug conjugates (ADC), and any combination thereof, either encapsulated in the LNP or attached to its surface (e.g., conjugated). Also provided are lipids, pharmaceutical compositions, kits, and methods of treatment.
Resumen de: US2025161480A1
The present invention relates to the technical field of biomedicines and vaccines, and in particular to an aluminum nanocrystalline composite immune drug and a preparation method therefor and use thereof. The aluminum nanocrystalline is used as a carrier, the surface of the aluminum nanocrystalline is covered with polyethylene glycol, and functional polypeptide sequences and cytokine molecules are linked by a polyethylene glycol end group to form a virus-like particle immune drug. According to the drug, the cytokine stability and the tumor tissue retention time are improved, and the auxiliary anti-tumor effect of the cytokines is effectively improved.
Resumen de: US2025161533A1
Provided herein are bioresorbable, bioregenerative composite materials and compositions to regenerate tissues or organs to repair tissue or organ defects and constructs printed from the same as 3D structures shaped and sized to fill a tissue or organ defect. The composite materials are bioresorbable polymers, for example, polycaprolactone, and a bioresorbable graft material, for example, demineralized bone matrix. Also provided are methods for making the composite materials and compositions and methods for regenerating tissues or organs and repairing a tissue or organ defect using the constructs.
Resumen de: US2025161434A1
Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic coronavirus proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.
Resumen de: US2025161462A1
The disclosure provides for compounds and compositions comprising hydrophilic-masked cationic charge dendrimers, and applications thereof, including delivering siRNA, ASO, PMO, PNA, oligonucleotide and nucleic acid vectors. The methods and approaches disclosed herein can also be applied to lipids to make hydrophilic-masked cationic charge lipid nanoparticles for mRNA, RNA, siRNA, DNA, ASO, PMO, PNA, oligonucleotide and nucleic acid vector delivery.
Resumen de: US2025161400A1
Bioavailable compositions comprising nanoparticulated ingredients in aqueous solution, methods of making the same, and methods of administering the same. A method includes providing an effective amount of a composition to an animal to reduce oxidative stress in the animal. The composition includes a water solvent and a nanoparticulated ingredient, wherein the nanoparticulated ingredient comprises one or more of nanoparticulated glutathione, nanoparticulated l-cysteine, nanoparticulated curcumin, or nanoparticulated collagen.
Resumen de: US2025161350A1
The invention relates to shape-specific cerium oxide nanoparticles (CNPs). methods of preparing CNPs. and methods of using CNPs to treat and/or inhibit and/or reduce and/or reverse the complications of respiratory syncytial virus (RSV) disease and other infections that cause pathologic immune responses. through the balance of favorable immunomodulation and reduced lung immunopathology. CNPs have the capability to switch between Ce3+ and Ce4+ oxidation states (e.g., to scavenge reactive oxygen species). The shape-specific CNPs are synthesized into various shapes and sizes. These properties offer an opportunity to utilize CNPs to modulate macrophage phenotypes along the spectrum of M1 and M2 phenotypes to combat RSV infection and other infections that cause pathologic immune responses.
Resumen de: WO2025106912A1
Gas-bubble based degrading liquid foams to deliver nucleic acids are disclosed. The nucleic acids can be delivered for a variety of research, diagnostic, and therapeutic uses, such as in situ CAR T and stem cell engineering. The foams can also be used for administration of therapeutic nucleic acids to anatomical sites, such as cancer sites, through direct application at the site or through the use of edible or drinkable foams in the case of esophageal cancers, the use of rectally applied foams to treat rectal or colorectal cancer, or the use of intraperitoneally injected foam to treat widespread ovarian cancer. The nucleic acids can be delivered in a vector, such as a lipid nanoparticle or a viral vector.
Resumen de: WO2025106590A1
A modified myoferlin protein capable of being packaged into extracellular vesicles (EVs) to facilitate release of EV payloads into recipient cells. The modified myoferlin protein enhances the release of payload at the targeted site. The present invention further provides a modified myoferlin-encapsulating nanoparticle comprising an exosome encapsulating any embodiment of the modified myoferlin of the present invention and one or more cargo RNAs to enhance release of the cargo RNAs at the targeted site.
Resumen de: WO2025106045A1
The invention relates to a dissolving microneedle containing nanoparticles loaded with a Receptor-Binding Domain (RBD).
Resumen de: WO2025103414A1
The present invention relates to a preparation method for and the use of lipid nanoparticles. Specifically, provided is a freeze-dried composition, comprising lipid nanoparticles and sodium chloride, wherein the lipid nanoparticles comprise at least one cationic lipid, and the weight ratio of sodium chloride to the cationic lipid is 1:10-10:1
Resumen de: WO2025103396A1
A pharmaceutical composition comprising a nucleic acid construct and the medical use thereof. Specifically, the present invention relates to a lipid nanoparticle comprising a nucleic acid construct represented by formula I, which can achieve highly efficient delivery of a exogenous target gene, allowing the exogenous target gene to be highly efficiently and rapidly expressed in the body. The present invention has the advantages of no gene integration risk and being easy to scale up to an industrial level, is a more ideal treatment approach than naked plasmids, and can be used as a gene therapy drug for a plurality of diseases.
Resumen de: WO2025102910A1
A biotin or avidin-labeled fat body, a preparation method therefor, and a nano-carrier system. A specific amount of bio-phospholipid or avidin-phospholipid is used to prepare a biotin or avidin labeled fat body. The prepared fat body has the advantages of high purity, small particle size, good uniformity and high stability. A nano-carrier system is constructed on the basis of the biotin-avidin system, and the nano-carrier system comprises the biotin-labeled fat body and an avidin-modified target component. By utilizing the system, the fat body can carry any substance of interest, for example protein drugs such as virus recombinant proteins, and antibodies, nucleic acid drugs or small molecule drugs, thereby being used for vaccines and the treatment of diseases such as cancers, infectious diseases and metabolic diseases.
Resumen de: WO2025102670A1
A nanoparticle adiposome encapsulating a hydrophobic small-molecule drug, a preparation method therefor, and a use thereof. The nanoparticle adiposome encapsulating the hydrophobic small-molecule drug comprises a monomolecular phospholipid membrane and hydrophobic small-molecule drug-containing neutral lipids encapsulated within the monomolecular phospholipid membrane. The nanoparticle adiposome has the hydrophobic small-molecule drug-containing neutral lipids as a hydrophobic core, and nanobeads wrapped by the monomolecular phospholipid membrane can efficiently dissolve and encapsulate a hydrophobic small-molecule compound. In addition, the adiposome encapsulating the hydrophobic small-molecule drug has bioactivity, can remarkably kill cancer cells, and has a killing effect superior to that of a free drug. In addition, the preparation method is simple and efficient. Therefore, the adiposome is a prospecting hydrophobic small-molecule drug delivery platform, and can be widely applied to the treatment of diseases such as cancer, infectious diseases and metabolic diseases.
Resumen de: WO2025102275A1
A preparation method for an engineered extracellular vesicle targeting oncofetal chondroitin sulfate-positive cells, and the use of same, belonging to the technical field of biomedicines. The present invention provides an engineered extracellular vesicle targeting oncofetal chondroitin sulfate-positive cells, which is obtained by collecting a supernatant of cells that stably overexpress a protein containing ofCSbps and separating same, the sequence of the ofCSbps being one of or a combined polypeptide sequence of more than one of SEQ ID NO. 1-7, or a derived sequence taking one polypeptide sequence of SEQ ID NO. 1-7 as a backbone, or a derived sequence taking a combined polypeptide sequence of more than one of SEQ ID NO. 1-7 as a backbone. The engineered extracellular vesicle of the present invention has the characteristic of targeting ofCS-positive cells. Since extracellular vesicles have nanoscale liposome encapsulation structures, the present invention is suitable for basic research and clinical diagnosis and treatment application on various diseases, such as placenta-derived physiological/pathological and tumor/cancer diseases, in humans and animals.
Resumen de: WO2025102261A1
Lipid compounds for delivering a therapeutic agent, a preparation method therefor and the use thereof. The lipid compounds are compounds with structural formula (I) or pharmaceutically acceptable forms thereof. The lipid compounds may be used in combination with other lipid components, such as neutral lipids, cholesterol, and polymer-bound lipids, so as to form lipid nanoparticles used for delivery of therapeutic agents (e.g. nucleic acid molecules) to achieve therapeutic or prophylactic purposes (e.g. vaccination), thus enriching the types of ionizable lipid compounds.
Resumen de: WO2024133486A1
The present invention pertains to a composition comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of nucleic acids in the lipid bilayer. The present invention furthermore pertains to said composition, for use in preventing and/or treating a disease, in particular for use in preventing and/or treating cancer. The present invention furthermore pertains to a method for producing a composition comprising said nucleic acid-lipids particles.
Resumen de: AU2025203126A1
Disclosed herein are stereocomplexes for the delivery of one or more anti cancer agents. The stereocomplexes exhibit low toxicity and are biodegradable while also providing for controlled release of one or more anti-cancer agents at tumor sites. The stereocomplexes can be designed such that the anti-cancer agents operate synergistically and may optionally include additional targeting groups and functionalities. The stereocomplexes disclosed herein can be combined with pharmaceutically-acceptable carriers and/or excipients to form pharmaceutical compositions. By varying the amount of each anti-cancer agent in the stereocomplex, specific types of tumors and cancer cell lines can be treated.
Resumen de: AU2023357035A1
The present invention relates to cell permeant particles. In particular, the present invention relates to plasma-treated particles or plasma-synthesised particles that are capable of migrating across the membranes of live cells.
Resumen de: AU2023382803A1
The present invention relates to a nanoparticle composition for drug delivery and, more specifically, to a composition for drug delivery, wherein the composition comprises an amphiphilic block copolymer and a lipid with a specific structure that can easily form complexes with anionic drugs, whereby the composition can easily form drug-containing nanoparticles and thus is useful for drug delivery, especially for targeted delivery of drugs to the lungs.
Nº publicación: AU2023385485A1 22/05/2025
Solicitante:
THE REGENTS OF THE UNIV OF CALIFORNIA
AALBORG UNIV
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA,
AALBORG UNIVERSITET
Resumen de: AU2023385485A1
The present disclosure provides inhibitory nucleic acids, compositions comprising the inhibitory nucleic acids, and methods of using the inhibitory nucleic acids to treat various disorders.
BOPI
Sede Electrónica
